ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 유전성 혈관부종 시장 규모는 앞으로 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.4%로 39억 3,000만 달러로 성장할 것으로 보입니다. 예측 기간 동안의 성장 요인으로는 희귀질환의 유병률 증가, 의료비 증가, 비영리 단체의 지원 확대, 유전성 혈관부종에 대한 의식 증가, 조기 진단에 대한 관심 증가 등이 있습니다. 예측기간의 주요 동향으로는 기술 혁신, 새로운 치료법의 개발, 신약의 도입, 진단 툴의 진보, 유전자 검사의 진보 등을 들 수 있습니다.
희귀질환의 유병률 증가는 향후 몇 년간의 유전성 혈관부종(HAE) 시장의 성장을 이끌 것으로 예측됩니다. 희귀질환은 종종 희소질환으로 불리우며 인구의 극히 일부에 영향을 미치지만, 그 유병률의 상승은 의료연구의 진보, 인구동태의 변화, 환경의 변화 등의 요인에 기인하고 있습니다. 유전성 혈관부종은 주목할 만한 희귀 질병이며 생명을 위협할 수 있는 부종 에피소드로 인해 전문적인 치료와 인지의 필요성을 강조합니다. 그 유전적 특성과 희소성은 조기 진단과 표적 치료가 환자의 결과를 개선하는 데 매우 중요합니다. Rare Disease Advisor에 따르면 2022년 6월 현재 HAE는 약 50,000명에 1명의 비율로 발병하였으며, 유병률은 1만명당 1명에서 15만명으로 1명으로 추정되고 있습니다. 미국에서 HAE의 에피소드는 연간 약 1만 5,000-3만건의 구급 외래 진찰을 차지하고 있습니다. 그 결과, 희귀질환의 증례 수 증가가 유전성 혈관부종 시장의 확대에 박차를 가하고 있습니다.
유전성 혈관부종 시장의 주요 기업은 환자에게 편리하고 효과적인 주문형 치료 솔루션을 제공하기 위해 경구 혈장 칼리크레인 억제제와 같은 획기적인 제품을 개발하기 위해 노력하고 있습니다. 이러한 억제제는 혈장 칼리크레인을 억제하여 유전성 혈관부종 치료의 중심이 되는 브라디키닌의 과잉생산을 막는 작용을 합니다. KalVista Pharmaceuticals, Inc.는 경구 혈장 칼리크레인 억제제인 Sebetralstat의 신약 승인 신청(NDA)이 FDA에 접수되었다고 발표했습니다. Sebetralstat는 12세 이상의 성인과 소아 환자에서 유전성 혈관부종 발작의 온디맨드 치료로 설계되어 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 유전성 혈관부종 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 유전성 혈관부종 시장 : 성장률 분석
세계의 유전성 혈관부종 시장 실적 : 규모와 성장, 2019-2024년
세계의 유전성 혈관부종 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 유전성 혈관부종 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 유전성 혈관부종 시장 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
유전성 혈관부종 유형 I
유전성 혈관부종 유형 II
세계의 유전성 혈관부종 시장 : 치료 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
예방
온디맨드
세계의 유전성 혈관부종 시장 : 약제 클래스별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
C-1 에스테라아제 억제제
브라지키닌 수용체 길항제
칼리크레인 억제제
기타
세계의 유전성 혈관부종 시장 : 투여 경로별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
피하
정맥내
경구
세계의 유전성 혈관부종 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 유전성 혈관부종 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 유전성 혈관부종 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
유전성 혈관부종 시장 : 경쟁 구도
유전성 혈관부종 시장 : 기업 프로파일
Intellia Therapeutics Inc.
Sanofi SA
Takeda Pharmaceutical Company Limited
Otsuka Pharmaceutical Co. Ltd.
CSL Limited
제31장 기타 주요 기업 및 혁신 기업
Cipla Limited
BioMarin Pharmaceutical Inc.
Ionis Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc.
Spark Therapeutics Inc.
Pharming Group NV
Pharvaris NV
Astria Therapeutics Inc.
CENTOGENE NV
KalVista Pharmaceuticals Inc.
ADARx Pharmaceuticals Inc.
Adverum BIoTechnologies Inc.
Attune Pharmaceuticals Inc.
Lev Pharmaceuticals Inc
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
유전성 혈관부종 시장(2029년) : 새로운 기회를 제공하는 국가
유전성 혈관부종 시장(2029년) : 새로운 기회를 제공하는 부문
유전성 혈관부종 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
JHS
영문 목차
영문목차
Hereditary angioedema (HAE) is a rare genetic condition marked by recurrent episodes of severe swelling in the skin, gastrointestinal tract, and airways, resulting from a deficiency or dysfunction of C1 esterase inhibitor. This disorder is caused by genetic mutations affecting the complement system, leading to an overproduction of bradykinin. HAE can be life-threatening if it causes airway swelling, which requires immediate treatment with C1 inhibitor replacement or therapies targeting bradykinin.
The primary types of hereditary angioedema are type I and type II. Type I HAE, the most common form, is caused by a deficiency of C1 esterase inhibitor (C1-INH), resulting in uncontrolled bradykinin production and repeated episodes of swelling. Treatment for HAE is generally categorized into prophylactic and on-demand approaches, utilizing various drug classes such as C1 esterase inhibitors, bradykinin receptor antagonists, kallikrein inhibitors, and others. These treatments are delivered through different methods, including subcutaneous, intravenous, and oral routes, and are available via hospital pharmacies, retail pharmacies, and online pharmacies.
The hereditary angioedema market research report is one of a series of new reports from The Business Research Company that provides hereditary angioedema market statistics, including the hereditary angioedema industry global market size, regional shares, competitors with the hereditary angioedema market share, detailed hereditary angioedema market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary angioedema industry. This hereditary angioedema market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The hereditary angioedema market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.84 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period can be attributed to factors such as the rising prevalence of hereditary angioedema, increased investment in research and development, a higher number of drug approvals, growing product approvals, and an increase in disposable income.
The hereditary angioedema market size is expected to see strong growth in the next few years. It will grow to $3.93 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth during the forecast period can be attributed to factors such as the increasing prevalence of rare diseases, rising medical expenditure, greater support from non-profit organizations, heightened awareness of hereditary angioedema, and a growing focus on early diagnosis. Key trends in the forecast period include technological innovations, the development of new therapies, the introduction of new drugs, advancements in diagnostic tools, and progress in genetic testing.
The increasing prevalence of rare diseases is expected to drive the growth of the hereditary angioedema (HAE) market in the coming years. Rare diseases, often referred to as orphan diseases, affect a small segment of the population, and their rising prevalence can be attributed to factors such as advancements in medical research, demographic shifts, and environmental changes. Hereditary angioedema, a notable rare disease, underscores the need for specialized treatments and awareness due to its potentially life-threatening swelling episodes. Its genetic nature and rarity make early diagnosis and targeted therapies crucial for better patient outcomes. According to Rare Disease Advisor, as of June 2022, HAE affects around 1 in 50,000 individuals, with prevalence estimates ranging from 1 in 10,000 to 1 in 150,000. In the U.S., HAE episodes account for approximately 15,000 to 30,000 emergency room visits annually. As a result, the growing number of rare disease cases is fueling the expansion of the hereditary angioedema market.
Leading companies in the hereditary angioedema market are working on developing groundbreaking products, such as oral plasma kallikrein inhibitors, to offer more convenient and effective on-demand treatment solutions for patients. These inhibitors work by blocking plasma kallikrein to prevent excessive production of bradykinin, which is central to treating hereditary angioedema. For example, in September 2024, KalVista Pharmaceuticals, Inc., a U.S.-based pharmaceutical company, announced that the FDA had accepted its new drug application (NDA) for sebetralstat, an oral plasma kallikrein inhibitor. Sebetralstat is designed for on-demand treatment of hereditary angioedema attacks in both adult and pediatric patients aged 12 and older. The NDA acceptance marks an important step towards the drug's potential approval and commercialization.
In July 2023, BioCryst Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company, partnered with Er-Kim Pharmaceuticals to commercialize ORLADEYO (berotralstat) in Turkey. This collaboration aims to improve access to ORLADEYO for hereditary angioedema patients in Turkey while expanding BioCryst's presence in the global rare disease market. Er-Kim Pharmaceuticals is a Turkish company dedicated to the development, manufacturing, and marketing of high-quality medicines across various therapeutic areas.
Major players in the hereditary angioedema market are Intellia Therapeutics Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., CSL Limited, Cipla Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Spark Therapeutics Inc., Pharming Group N.V., Pharvaris N.V., Astria Therapeutics Inc., CENTOGENE N.V., KalVista Pharmaceuticals Inc., ADARx Pharmaceuticals Inc., Adverum Biotechnologies Inc., Attune Pharmaceuticals Inc., and Lev Pharmaceuticals Inc.
North America was the largest region in the hereditary angioedema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hereditary angioedema report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the hereditary angioedema market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hereditary angioedema market consists of revenues earned by entities by providing services such as diagnosis and genetic testing, acute attack management, and long-term prevention. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary angioedema market also includes sales of plasma-derived products, biologics, and therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hereditary Angioedema Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on hereditary angioedema market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for hereditary angioedema ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hereditary angioedema market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Hereditary Angioedema Type I; Hereditary Angioedema Type II
2) By Treatment Type: Prophylaxis; On-demand
3) By Drug Class: C-1 Esterase Inhibitors; Bradykynin Receptor Antagonist; Kallikrein Inhibitors; Other Drug Classes
4) By Route Of Administration: Subcutaneous; Intravenous; Oral
5) By Distribution channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency; Low C1-Inhibitor Levels; Reduced C1-Inhibitor Function
2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels; Dysfunctional C1-Inhibitor; Genetic Mutations In SERPING1 Gene
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Hereditary Angioedema Market Characteristics
3. Hereditary Angioedema Market Trends And Strategies
4. Hereditary Angioedema Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Hereditary Angioedema Growth Analysis And Strategic Analysis Framework
5.1. Global Hereditary Angioedema PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Hereditary Angioedema Market Growth Rate Analysis
5.4. Global Hereditary Angioedema Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Hereditary Angioedema Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Hereditary Angioedema Total Addressable Market (TAM)
6. Hereditary Angioedema Market Segmentation
6.1. Global Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hereditary Angioedema Type I
Hereditary Angioedema Type II
6.2. Global Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prophylaxis
On-demand
6.3. Global Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
C-1 Esterase Inhibitors
Bradykynin Receptor Antagonist
Kallikrein Inhibitors
Other Drug Classes
6.4. Global Hereditary Angioedema Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Subcutaneous
Intravenous
Oral
6.5. Global Hereditary Angioedema Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.6. Global Hereditary Angioedema Market, Sub-Segmentation Of Hereditary Angioedema Type I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
C1-Inhibitor Deficiency
Low C1-Inhibitor Levels
Reduced C1-Inhibitor Function
6.7. Global Hereditary Angioedema Market, Sub-Segmentation Of Hereditary Angioedema Type II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Normal C1-Inhibitor Levels
Dysfunctional C1-Inhibitor
Genetic Mutations In SERPING1 Gene
7. Hereditary Angioedema Market Regional And Country Analysis
7.1. Global Hereditary Angioedema Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Hereditary Angioedema Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
